Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Cryptosporidium parvum | inosine-5-monophosphate dehydrogenase | Starlite/ChEMBL | References |
Homo sapiens | IMP (inosine 5'-monophosphate) dehydrogenase 2 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | kinesin, putative | 0.0915154 | 0.118371 | 0.5 |
Echinococcus multilocularis | kinesin family 1 | 0.692914 | 1 | 1 |
Trypanosoma cruzi | inosine-5'-monophosphate dehydrogenase, putative | 0.0232075 | 0.0182334 | 0.5 |
Toxoplasma gondii | kinesin motor domain-containing protein | 0.0915154 | 0.118371 | 1 |
Schistosoma mansoni | kinesin eg-5 | 0.0915154 | 0.118371 | 0.118141 |
Loa Loa (eye worm) | kinesin-like protein KLP2 | 0.0915154 | 0.118371 | 1 |
Mycobacterium leprae | Probable inosine-5'-monophosphate dehydrogenase GuaB2 (IMP dehydrogenase) (IMPDH) (IMPD) | 0.0232075 | 0.0182334 | 1 |
Mycobacterium tuberculosis | Probable inosine-5'-monophosphate dehydrogenase GuaB2 (imp dehydrogenase) (inosinic acid dehydrogenase) (inosinate dehydrogenase | 0.0232075 | 0.0182334 | 1 |
Giardia lamblia | Kinesin-5 | 0.0915154 | 0.118371 | 0.5 |
Leishmania major | inosine-5-monophosphate dehydrogenase | 0.0232075 | 0.0182334 | 0.5 |
Trypanosoma brucei | inosine-5'-monophosphate dehydrogenase | 0.0232075 | 0.0182334 | 0.5 |
Trypanosoma brucei | GMP reductase | 0.0232075 | 0.0182334 | 0.5 |
Plasmodium vivax | kinesin-5 | 0.0915154 | 0.118371 | 1 |
Mycobacterium ulcerans | inosine 5-monophosphate dehydrogenase | 0.0227259 | 0.0175274 | 0.961281 |
Plasmodium falciparum | kinesin-5 | 0.0915154 | 0.118371 | 1 |
Brugia malayi | Kinesin motor domain containing protein | 0.0915154 | 0.118371 | 1 |
Wolbachia endosymbiont of Brugia malayi | IMP dehydrogenase | 0.0232075 | 0.0182334 | 0.5 |
Trypanosoma cruzi | GMP reductase | 0.0232075 | 0.0182334 | 0.5 |
Mycobacterium leprae | Probable inosine-5'-monophosphate dehydrogenase GuaB3 (IMP dehydrogenase 2) (inosinic acid dehydrogenase) (inosinate dehydrogena | 0.0124378 | 0.00244547 | 0.13412 |
Leishmania major | guanosine monophosphate reductase | 0.0232075 | 0.0182334 | 0.5 |
Echinococcus granulosus | kinesin family 1 | 0.692914 | 1 | 1 |
Mycobacterium ulcerans | inosine 5'-monophosphate dehydrogenase | 0.0232075 | 0.0182334 | 1 |
Schistosoma mansoni | hypothetical protein | 0.601399 | 0.865842 | 1 |
Trypanosoma cruzi | inosine-5'-monophosphate dehydrogenase, putative | 0.0232075 | 0.0182334 | 0.5 |
Trypanosoma cruzi | inosine-5'-monophosphate dehydrogenase, putative | 0.0232075 | 0.0182334 | 0.5 |
Trypanosoma cruzi | GMP reductase | 0.0232075 | 0.0182334 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 0.19 uM | Antiparasitic activity against transgenic Toxoplasma gondii expressing Cryptosporidium parvum IMPDH | ChEMBL. | 23668331 |
IC50 (binding) | = 2.3 nM | Inhibition of Cryptosporidium parvum N-terminal His6-tagged IMPDH-mediated NADH production expressed in Escherichia coli BL21(DE3) preincubated for 5 mins prior to substrate addition by fluorescence assay | ChEMBL. | 23668331 |
IC50 (binding) | = 6 nM | Inhibition of Cryptosporidium parvum N-terminal His6-tagged IMPDH-mediated NADH production expressed in Escherichia coli BL21(DE3) preincubated for 5 mins prior to substrate addition by fluorescence assay in presence of BSA | ChEMBL. | 23668331 |
IC50 (binding) | > 5 uM | Inhibition of human IMPDH2 | ChEMBL. | 23668331 |
LD50 (ADMET) | > 50 uM | Cytotoxicity against human HEK293 cells after 3 days by Alamar blue assay | ChEMBL. | 23668331 |
Ratio EC50 (functional) | = 14 | Selectivity ratio of EC50 for wild-type Toxoplasma gondii to EC50 for Toxoplasma gondii expressing Cryptosporidium parvum IMPDH | ChEMBL. | 23668331 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Toxoplasma gondii | ChEMBL23 | 23668331 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.